Feasibility And Efficacy Of Neoadjuvant Cabozantinib And Nivolumab In Patients With Borderline Resectable Or Locally Advanced Hepatocellular Carcinoma (Hcc).

335Background: Only 10-15% of newly diagnosed HCC patients are candidates for a potentially curative resection, and most patients who receive resection eventually recur. Historical systemic therapi...